Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.61 |
| ▸ | FLT3 | P36888 | 8/20 | 0.61 |
| ▸ | FLT4 | P35916 | 4/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.58 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | AKT2 | P31751 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.54 |
| ▸ | FLT1 | P17948 | 2/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.54 |
| ▸ | STK3 | Q13188 | 2/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.54 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.54 |
| ▸ | LATS1 | O95835 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328278 | 1.00 | KDR (0.61) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328166 | 0.94 | KDR (0.61) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328168 | 0.94 | KDR (0.61) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328349 | 0.91 | FLT3 (0.62) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328347 | 0.91 | FLT3 (0.62) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328093 | 0.87 | FLT3 (0.64) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328095 | 0.87 | FLT3 (0.64) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328223 | 0.84 | AURKB (0.65) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328221 | 0.84 | AURKB (0.65) | KDRFLT3FLT4KITAURKB | |
| SCHEMBL15328062 | 0.81 | AURKB (0.68) | KDRFLT3FLT4KITAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | claimed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | claimed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | claimed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | KDR 1519/4885FLT3 1086/4885FLT4 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.